RxDoctor Payments DataLook up a doctor →

Lisa Selby

Nurse Practitioner · El Paso, TXNPI 1811599665

Payments from drug & device makers

$18,529in general payments, 2019–2025

Across 837 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Novo Nordisk$2K
  • Amgen$2K
  • Dexcom, Inc.$2K
  • Lilly USA, LLC$1K
  • Insulet Corporation$828
  • plus $8K from 38 others

What the payments were for

  • Travel & lodging$2,12611%
  • Food & beverage$16,33488%
  • Education$690%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,529 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
KorlymMifepristone38$1,265,305
MounjaroTirzepatide627$1,170,181
OzempicSemaglutide408$914,589
Synjardy XrEmpagliflozin/Metformin Hcl252$300,183
JardianceEmpagliflozin213$251,267
FarxigaDapagliflozin Propanediol215$243,047
TrulicityDulaglutide104$225,580
ProliaDenosumab119$207,416
Xigduo XrDapaglifloz Propaned/Metformin146$176,536
VascepaIcosapent Ethyl211$176,116
KerendiaFinerenone172$145,979
Humalog Kwikpen U-200Insulin Lispro53$133,178
Tresiba Flextouch U-200Insulin Degludec91$125,746
RybelsusSemaglutide56$110,704
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog69$101,270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$1,474$1,411,802765 claims
Corcept TherapeuticsKorlym$745$1,265,30538 claims
Novo NordiskOzempic, Rybelsus$2,091$1,025,293464 claims
Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy$417$583,265489 claims
AstraZenecaFarxiga$548$243,047215 claims
AmgenProlia$1,626$207,416119 claims
BayerKerendia$806$145,979172 claims
Radius Health, Inc.Tymlos$375$63,88314 claims
MerckJanuvia, Janumet$214$58,32352 claims
AbbVieLinzess, Synthroid$560$48,996156 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$309$18,01615 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$243$17,36517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →